Hematology NewsFDA Broadens Breyanzi’s Follicular Lymphoma IndicationMay 16, 2024Non-Hodgkin LymphomaCellular TherapyIndolent Lymphoma
Oncology PracticeSurvey Spotlights Identification of Dermatologic Adverse Events From Cancer TherapiesMay 13, 2024Mixed TopicsBreast CancerCNS/Brain CancerDLBCLFollicular LymphomaGastrointestinal CancerGenitourinary Cancer
Hematology NewsGlobal Quest to Cut CAR T CostsMay 6, 2024Cellular TherapyAggressive LymphomasALLAMLMultiple Myeloma
Hematology NewsTiny Doses of Metabolically Armed CAR T Show BenefitsApril 23, 2024Cellular TherapyALLDLBCLNon-Hodgkin Lymphoma
Hematology NewsTiming Is Everything: CAR T for Follicular LymphomaApril 18, 2024Non-Hodgkin LymphomaCellular Therapy
Oncology PracticeMost Targeted Cancer Drugs Lack Substantial Clinical BenefitApril 17, 2024Practice ManagementBreast CancerCNS/Brain CancerDLBCLFollicular LymphomaGastrointestinal CancerGenitourinary Cancer
Oncology PracticeLess Than 50% of Accelerated Approvals Show Clinical BenefitApril 9, 2024Practice ManagementBreast CancerCNS/Brain CancerDLBCLFollicular LymphomaGastrointestinal CancerGenitourinary Cancer
Hematology NewsAbecma Approved for Earlier Lines in Relapsed/Refractory Multiple MyelomaApril 9, 2024Multiple MyelomaCellular Therapy
Hematology NewsSecondary Cancers Post CAR T Therapy: A Concern?March 20, 2024Cellular TherapyAggressive LymphomasALLAMLAnemiaCLLCML
Hematology NewsMyeloma: FDA Advisers Greenlight Early CAR-TMarch 18, 2024Multiple MyelomaCellular Therapy
Hematology NewsFDA Approves First CAR T-Cell Therapy for rrCLL, rrSLLMarch 15, 2024CLLCellular Therapy
Hematology NewsHigh Marks for New CAR T Toxicity Grading ToolMarch 12, 2024Cellular TherapyB Cell LymphomaDLBCLMantle Cell LymphomaMultiple MyelomaTransplantMixed Topics
